.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Novartis
McKesson
McKinsey
Boehringer Ingelheim
Argus Health
Medtronic
Fuji
Teva

Generated: June 27, 2017

DrugPatentWatch Database Preview

Bazedoxifene acetate; estrogens, conjugated - Generic Drug Details

« Back to Dashboard

What are the generic sources for bazedoxifene acetate; estrogens, conjugated and what is the scope of bazedoxifene acetate; estrogens, conjugated patent protection?

Bazedoxifene acetate; estrogens, conjugated
is the generic ingredient in one branded drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bazedoxifene acetate; estrogens, conjugated has sixty-two patent family members in forty countries.

There are two drug master file entries for bazedoxifene acetate; estrogens, conjugated. Two suppliers are listed for this compound.

Summary for Generic Name: bazedoxifene acetate; estrogens, conjugated

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list2
Clinical Trials: see list1,179
Drug Prices:see low prices
DailyMed Link:bazedoxifene acetate; estrogens, conjugated at DailyMed

Pharmacology for Ingredient: bazedoxifene acetate; estrogens, conjugated

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes5,998,402► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes7,138,392► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes8,815,934► SubscribeY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes6,479,535► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: bazedoxifene acetate; estrogens, conjugated

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 20137,138,392► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: bazedoxifene acetate; estrogens, conjugated

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,291,451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,132,4172-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
6,232,307 Tissue selective compounds in the treatment of ovarian cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: bazedoxifene acetate; estrogens, conjugated

Country Document Number Estimated Expiration
Austria206701► Subscribe
European Patent Office0802183► Subscribe
Canada2558821► Subscribe
Ukraine85703► Subscribe
Guatemala200500078► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00035Denmark► Subscribe
2009007,C0802183Lithuania► SubscribePRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0802183/01Switzerland► SubscribePRODUCT NAME: BAZEDOXIFEN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58732 12.01.2010
2009007Lithuania► SubscribePRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0416Netherlands► Subscribe300416, 20170415, EXPIRES: 20220414
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chubb
Dow
Queensland Health
Novartis
Fuji
Citi
US Department of Justice
Cantor Fitzgerald
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot